A surprising obesity trial result has shaken confidence in Novo Nordisk (NVO +1.38%) and sharpened the spotlight on Eli Lilly (LLY 2.03%) in this fiercely competitive GLP‑1 race. Watch the video below to see what it could mean for investors. *This video was published on Feb.24, 2026. Andy Cross has no position in any of...

With a shrinking population and a collapsed property market, turning to a technology-led growth strategy was a logical step for China. The model has surpassed expectations, even with the fundamental flaw of being unable, for now, to create enough wealth to lift the fortunes of a broad slice of society.